Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
In order to assess the variation in expression of poly(ADP-ribose) polymerase (PARP) family members and the hydrolases that degrade the poly(ADP-ribose) polymers they generate and possible associations with classical pathological parameters, including long-term outcome, the mRNA levels of PARP1, PARP2, PARP3, poly(ADP-ribose) glycohydrolase (PARG) and ADP-ribosylhydrolase 3 (ARH3) were examined using quantitative reverse transcription polymerase chain reaction in 443 unilateral invasive breast cancers and linked to hormonal status, tumor proliferation and clinical outcome.
|
23736962 |
2013 |
Cerebral Infarction
|
0.010 |
Biomarker
|
disease |
BEFREE |
Consistent with the previous findings, the patient's fibroblasts and ARH3-deficient mice were more sensitive, respectively, to H2O2 stress and cerebral ischemia/reperfusion-induced PAR accumulation and cell death.
|
30830864 |
2019 |
Developmental delay (disorder)
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
We used exome sequencing to identify five different bi-allelic pathogenic ADPRHL2 variants in 12 individuals from 8 families affected by a neurodegenerative disorder manifesting in childhood or adolescence with key clinical features including developmental delay or regression, seizures, ataxia, and axonal (sensori-)motor neuropathy.
|
30401461 |
2018 |
Neurodegenerative Disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
We used exome sequencing to identify five different bi-allelic pathogenic ADPRHL2 variants in 12 individuals from 8 families affected by a neurodegenerative disorder manifesting in childhood or adolescence with key clinical features including developmental delay or regression, seizures, ataxia, and axonal (sensori-)motor neuropathy.
|
30401461 |
2018 |
Global developmental delay
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We used exome sequencing to identify five different bi-allelic pathogenic ADPRHL2 variants in 12 individuals from 8 families affected by a neurodegenerative disorder manifesting in childhood or adolescence with key clinical features including developmental delay or regression, seizures, ataxia, and axonal (sensori-)motor neuropathy.
|
30401461 |
2018 |
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
In the present review, research on ARH1-regulated tumorigenesis and cell death pathways that are enhanced by ARH3 deficiency are discussed.
|
30267646 |
2019 |
Mammary Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Variations in the mRNA expression of poly(ADP-ribose) polymerases, poly(ADP-ribose) glycohydrolase and ADP-ribosylhydrolase 3 in breast tumors and impact on clinical outcome.
|
23736962 |
2013 |
HYPERCHOLESTEROLEMIA, AUTOSOMAL RECESSIVE
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
ARH is rare except in Sardinia where three alleles (ARH1, ARH2 and ARH3) explain most of cases.
|
19477448 |
2009 |
NEURODEGENERATION, CHILDHOOD-ONSET, STRESS-INDUCED, WITH VARIABLE ATAXIA AND SEIZURES
|
0.600 |
GeneticVariation
|
disease |
CLINVAR |
|
|
|
NEURODEGENERATION, CHILDHOOD-ONSET, STRESS-INDUCED, WITH VARIABLE ATAXIA AND SEIZURES
|
0.600 |
CausalMutation
|
disease |
CLINVAR |
Bi-allelic ADPRHL2 Mutations Cause Neurodegeneration with Developmental Delay, Ataxia, and Axonal Neuropathy.
|
30401461 |
2018 |
Developmental regression
|
0.400 |
Biomarker
|
disease |
HPO |
|
|
|
Blepharoptosis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Dysarthria
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Nystagmus
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Ophthalmoplegia
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Ptosis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Babinski Reflex
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Strabismus
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Tremor
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Muscle Weakness
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Cerebellar Dysmetria
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Cerebral atrophy
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Fasciculation, Tongue
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Cerebellar atrophy
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Axonal loss
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|